Bioequivalence and Its Importance in Drug Formulation
Start with the big picture
Bioequivalence assessment compares products at the same molar dose under similar conditions, focusing on the rate and extent of absorption. Common measures include Cmax and AUC; Tmax can inform absorption rate, although it is not part of the stated confidence-interval acceptance criteria. The source describes acceptance criteria based on confidence intervals for log-transformed Cmax and AUC, alongside crossover study designs for average bioequivalence. It also identifies situations that may call for different assessment approaches, including narrow therapeutic index drugs, highly variable drugs, modified-release products, and certain biopharmaceutics classification system classes. Particle size, polymorph, excipients, and manufacturing processes can affect bioequivalence. The concept matters because results support decisions about interchangeability and the clinical and regulatory implications of formulation differences.
What you'll learn
- Define bioequivalence in terms of absorption rate and extent.
- Identify Cmax, AUC, and Tmax as measures used in bioequivalence assessment.
- Describe the general confidence-interval approach to acceptance criteria.
- Recognize study and formulation factors that can affect bioequivalence.
- Explain why bioequivalence findings matter for interchangeability and therapy.
Continue your study
Work through the complete notes and reinforce the topic with the study tools available in the full lesson.
